Vigil Neuroscience Patents – Key Insights and Stats

Vigil Neuroscience has a total of 43 patents globally, out of which 1 has been granted. Of these 43 patents, more than 93% patents are active. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Vigil Neuroscience.

Vigil Neuroscience was founded in the year 2020. The Company operates as a biotechnology company. The Company focuses on discovering and developing novel therapeutics in basic science and human genetics of microglia. As of May 2023, the market cap of Vigil Neuroscience is $356.67 Million.

Do read about some of the most popular patents of Vigil Neuroscience which have been covered by us in this article and also you can find Vigil Neuroscience patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Vigil Neuroscience patent portfolio.

How many patents does the CEO of Vigil Neuroscience have?

The CEO Ivana Magovčević-Liebisch has 0 patent.

How many patents does Vigil Neuroscience have?

Vigil Neuroscience has a total of 43 patents globally. These patents belong to 9 unique patent families. Out of 43 patents, 40 patents are active.

How Many Patents did Vigil Neuroscience File Every Year?

Vigil Neuroscience Patent Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantVigil Neuroscience Applications FiledVigil Neuroscience Patents Granted
202311
202214
202128

How many Vigil Neuroscience patents are Alive/Dead?

Vigil Neuroscience Patent Portfolio

 How Many Patents did Vigil Neuroscience File in Different Countries?

Vigil Neuroscience Worldwide Paent Filing

Countries in which Vigil Neuroscience Filed Patents

CountryPatents
Taiwan3
South Africa3
Australia3
United States Of America3
Brazil3
Canada3
Africa3
Ecuador2
India2
Colombia2
New Zealand2
Mexico2
Singapore2
Israel2
Argentina1
Indonesia1

Where are Research Centres of Vigil Neuroscience Patents Located?

R&D Centers of Vigil Neuroscience

What Percentage of Vigil Neuroscience US Patent Applications were Granted?

Vigil Neuroscience (Excluding its subsidiaries) has filed 2 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 0 have been granted leading to a grant rate of 0.0%.

Below are the key stats of Vigil Neuroscience patent prosecution at the USPTO.

Which Law Firms Filed Most US Patents for Vigil Neuroscience?

Law FirmTotal ApplicationsSuccess Rate
Dechert20%

List of Vigil Neuroscience Patents

Vigil Neuroscience PatentsTitle
US11608344B2Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use
US20230082623A1Treatment Of Diseases Related To Atp-Binding Cassette Transporter 1 Dysfunction Using Trem2 Agonists
US20220089726A1Treatment Of Diseases Related To Colony-Stimulating Factor 1 Receptor Dysfunction Using Trem2 Agonists
WO2022236272A3Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use
WO2022251868A1Trem2 Agonist Biomarkers And Methods Of Use Thereof
WO2022120390A1Treatment Of Diseases Related To Atp-Binding Cassette Transporter 1 Dysfunction Using Trem2 Agonists
WO2022032293A3Treatment Of Diseases Related To Colony-Stimulating Factor 1 Receptor Dysfunction Using Trem2 Agonists
WO2021226135A1Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use
WO2021226629A1Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use
BR112023002093A2Treatment Of Diseases Related To Colony Stimulating Factor 1 Receptor Dysfunction Using Train2 Agonists
AU2021320553A1Treatment Of Diseases Related To Colony-Stimulating Factor 1 Receptor Dysfunction Using Trem2 Agonists
TW202309029AHeterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use
APP2023014673A0Treatment Of Diseases Related To Colony-Stimulating Factor 1 Receptor Dysfunction Using Tremm2 Agonists
ZA202301372ATreatment Of Diseases Related To Colony-Stimulating Factor 1 Receptor Dysfunction Using Trem2 Agonists
BR112022022338A2Heterocyclic Compounds As An Express Trigger Receptor In Myeloid 2 Cell Agonists And Methods Of Use
BR112022022341A2Heterocyclic Compounds As An Express Trigger Receptor In Myeloid 2 Cell Agonists And Methods Of Use
APP2022014529A0Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use
APP2022014530A0Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use
AU2021267161A1Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use
AU2021266805A1Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use
ZA202211897AHeterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use
ZA202211896AHeterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use
TW202218683ATreatment Of Diseases Related To Colony-Stimulating Factor 1 Receptor Dysfunction Using Trem2 Agonists
TW202208355AHeterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use
CA3190581A1Treatment Of Diseases Related To Colony-Stimulating Factor 1 Receptor Dysfunction Using Trem2 Agonists
CA3182105A1Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use
CA3182541A1Heterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use
MX2022013838AHeterocyclic Compounds As Agonists Of The Activation Receptor Expressed On Myeloid Cells 2 And Methods Of Use
MX2022013842AHeterocyclic Compounds As Agonists Of The Activation Receptor Expressed On Myeloid Cells 2 And Methods Of Use
ECSP22089520AHeterocyclic Compounds As Trigger Receptors Expressed In Myeloid Cell 2 Agonists And Methods Of Use
ECSP22089527AHeterocyclic Compounds As Trigger Receptors Expressed In Myeloid Cell 2 Agonists And Methods Of Use
IN202217062928AHeterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use
IN202217062929AHeterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use
CO20220015927A2Heterocyclic Compounds As Agonists Of The Activation Receptor Expressed In Myeloid Cells 2 And Methods Of Use
CO20220015930A2Heterocyclic Compounds As Agonists Of The Activation Receptor Expressed In Myeloid Cells 2
SG11202254287BAHeterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use
SG11202254290MAHeterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use
NZ793874AHeterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use
NZ794078AHeterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use
ID202301905AHeterosyclic Compounds As Trigger Receptors Expressed In Mieloid 2 Cell Agonists And Methods Of Their Use
IL297833AHeterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use
IL297845AHeterocyclic Compounds As Triggering Receptor Expressed On Myeloid Cells 2 Agonists And Methods Of Use
AR122010A1Heterocyclic Compounds As Trigging Receptors Expressed In Myeloid 2 Cell Agonists And Methods Of Use

What are Vigil Neuroscience key innovation segments?

What Technologies are Covered by Vigil Neuroscience?

The chart below distributes patents filed by Vigil Neuroscience in different countries on the basis of the technology protected in patents. It also represents the markets where Vigil Neuroscience thinks it’s important to protect particular technology inventions.

R&D Focus: How has Vigil Neuroscience search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Vigil Neuroscience?

Related Articles

Clobotics Patents – Insights & Stats (Updated 2024)

Clobotics has a total of 160 patents globally, out of which 81 have been granted. Of these 160 patents, more than 61% patents are active. China is where Clobotics has filed the maximum number of patents, followed by United States of America and Mexico. Parallelly, China seems to be the

Read More »

Leave a Comment

Fill the form to get the details:

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.